Supriya Lifescience Reports Strong Financial Results for Q3 2024, Receives 'Buy' Rating
Supriya Lifescience, a midcap pharmaceutical company, has reported strong financial results for the quarter ending September 2024. The company's operating profit, operating profit margin, profit before tax, profit after tax, and net sales have all shown growth in the last five quarters, indicating a positive trend in the company's near-term performance.
Supriya Lifescience, a midcap pharmaceutical company, has recently announced its financial results for the quarter ending September 2024. The company has shown a very positive performance in this quarter, with its score improving from 18 to 21 in the last 3 months.One of the key factors contributing to this success is the company's operating profit (PBDIT), which has been the highest at Rs 64.71 crore and has shown growth in each of the last five quarters. This indicates a positive trend in the company's near-term operating profit.
Furthermore, Supriya Lifescience has also seen a significant improvement in its operating profit margin, which has been the highest at 38.96% and has shown growth in each of the last five quarters. This reflects the company's improved efficiency.
In terms of profit before tax (PBT) less other income, Supriya Lifescience has achieved its highest at Rs 59.54 crore and has shown growth in each of the last five quarters. This is a very positive trend in the company's near-term PBT.
Similarly, the company's profit after tax (PAT) has also been the highest at Rs 46.15 crore and has shown growth in each of the last five quarters. This indicates a very positive trend in the company's near-term PAT.
Moreover, Supriya Lifescience has also seen a positive trend in its net sales, with the highest at Rs 166.10 crore in the last five quarters. This further reinforces the company's strong performance in this quarter.
In conclusion, Supriya Lifescience's financial results for the quarter ending September 2024 have been very positive, with a significant improvement in key financial indicators. This has led to MarketsMOJO giving a 'Buy' call for the company's stock. With increasing profitability and higher earnings per share, Supriya Lifescience has shown its potential for growth in the pharmaceutical industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
